Business Context and Reporting Period
Company: Curis, Inc. (CRIS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Reporting Period: The filing reports on events occurring on November 6, 2025, and references financial results for the three- and nine-month periods ended September 30, 2025.
Key Financial Metrics and Transaction Details
- Asset Disposition: Sold its interest in Curis Royalty LLC (the "Erivedge Business") to TPC Investments Royalty LLC (managed by Oberland Capital Management).
- Consideration Received: $2.5 million in upfront cash.
- Liability Extinguished: The transaction released the Company from its liability related to the prior sale of future royalties to Oberland.
- Revenue Impact: Following the sale, the Company will no longer be entitled to revenues under the Genentech License Agreement for Erivedge (vismodegib).
- Accounting Impact: The Company expects to recognize a gain in the fourth quarter of 2025 statement of operations and comprehensive loss.
- Stockholders' Equity: Management believes the transaction has resulted in stockholders' equity well in excess of the $2.5 million requirement for Nasdaq continued listing.
Note: Specific revenue, profit, cash flow, and margin figures for the period ended September 30, 2025, are not provided in this filing text; they are referenced in an attached press release (Exhibit 99.1).
Material Changes and Risks
Nasdaq Listing Status
- Previous Deficiency: The Company failed to meet the Nasdaq Market Value of Listed Securities (MVLS) requirement of $35,000,000.
- Current Status: On October 20, 2025, the Nasdaq Hearings Panel granted an exception until November 14, 2025, to regain compliance.
- Compliance Strategy: The Company asserts that the sale of the Erivedge Business has restored stockholders' equity above the $2.5 million alternative listing standard.
- Risk: There is no assurance that the Panel will determine the Company has regained compliance or that the Company will remain listed on the Nasdaq Capital Market.
Termination of Material Agreement
The sale effectively terminates the Company's rights and obligations under the 2003 Collaborative Research, Development and License Agreement with Genentech regarding Erivedge royalties, transferring these rights to Curis Royalty LLC (now owned by the buyer).
Guidance and Management Commentary
- Outlook: The Company is pursuing several alternatives to regain compliance with Nasdaq listing rules, with the recent asset sale being a primary mechanism to improve equity position.
- Future Operations: The Company will no longer generate royalty revenue from Erivedge sales post-closing.
- Pro Forma Data: Unaudited pro forma condensed consolidated financial information reflecting the sale will be filed within four business days of the closing date.
Investor Verification Checklist
- Verify the exact amount of the gain recognized in Q4 2025 related to the extinguishment of the royalty liability.
- Review the press release (Exhibit 99.1) for specific revenue and cash flow figures for the nine months ended September 30, 2025.
- Monitor the Nasdaq Hearings Panel's final determination regarding the Company's compliance status by November 14, 2025.
- Confirm the filing of the pro forma financial statements to understand the post-transaction capital structure.
- Assess the Company's remaining pipeline and revenue sources now that the Erivedge royalty stream has been divested.